Compound 2 was able tostrongly inhibit the growthof leukemia, melanoma and breast cancer cell lines in the NCI-60 antiproliferationscreen (Table S3), in agreement with the published anti-proliferative effects ofCBP/EP300-BRD inhibitors in leukemia lines.,, It was, thus, not surprising to observea reduction in THP-1 cell proliferation following a 3 day treatmentwith all of our tested compounds (Figure e), likely due, at least in part, to theireffects on myc expression (Figure e,g). The gene discussed is MYC; the disease is breast cancer.